



**FOR IMMEDIATE RELEASE**

**Contact:**

QIAGEN N.V.

Peer M. Schatz  
Chief Financial Officer  
011 49 2103 892 702  
e-mail: [p.schatz@de.QIAGEN.com](mailto:p.schatz@de.QIAGEN.com)

Noonan/Russo Communications, Inc.  
Amy Martini (investor) ext. 255  
Renee Solano (media) ext.227  
(212) 696-4455  
e-mail: [news@nrp-euro.com](mailto:news@nrp-euro.com)

**QIAGEN ANNOUNCES APPOINTMENT OF DONALD E. SCHOENY AS VICE  
PRESIDENT - COMMERCIAL OPERATIONS  
- Responsible for Worldwide Sales and Marketing -**

**Valencia, California (USA), January 11, 1999** - QIAGEN Inc., a subsidiary of QIAGEN N.V. (Nasdaq: QGENF, Neuer Markt: QIA) today announced the appointment of Donald E. Schoeny as Vice President - Commercial Operations.

In this newly created position, Mr. Schoeny will assume responsibility for all marketing and sales functions worldwide. He will report to Dr. Metin Colpan, QIAGEN's Chief Executive Officer.

QIAGEN believes that the quality and performance of its marketing and sales activities have been key factors in the company's strong growth and profitability. The Company believes that its technically sophisticated and responsive sales force and support staff and its dynamic marketing staff form one of the strongest sales and marketing groups in QIAGEN's industry. Besides the major marketing and sales centers in Los Angeles (USA) and Hilden (Germany), QIAGEN has active subsidiaries in Japan, the United Kingdom, Switzerland, France, Australia and Canada. In his function as Vice President -Commercial Operations, Mr. Schoeny will be responsible for the activities and success of these resources.

Donald E. Schoeny brings to QIAGEN 29 years of experience in marketing, sales and service management as well as a strong international background.

Mr. Schoeny joins QIAGEN from PerSeptive BioSystems Inc. where he was the Senior Vice President of Sales, Service and Technical Support from 1997 to 1998. Perkin-Elmer Corp. (NYSE: PKN) purchased the company in 1998. Between 1969 and 1997, Mr. Schoeny held a range of positions in marketing, sales and support management in the analytical/life science, instrumentation and computer businesses of Hewlett-Packard Company (NYSE: HWP). From 1984 to 1997, he held the position of Group Marketing Manager, responsible for worldwide sales, marketing, and support of Hewlett-Packard's Chemical Analysis Group with fiscal 1997 revenues of approximately \$900 million. During this period Mr. Schoeny directed the activities that helped the Chemical Analysis Group gain a market leadership role and industry reputation for superior quality and service.

Donald E. Schoeny received Bachelors and Masters Degrees in Aerospace Engineering from the University of Southern California. He also received business management education from INSEAD, Fontainebleau, France.

"We are excited to bring Don Schoeny to QIAGEN," said Dr. Metin Colpan, QIAGEN's Chief Executive Officer. "Don's extensive experience in marketing and sales will be a great asset to QIAGEN. He has a deep-seated commitment to quality and customer satisfaction that matches QIAGEN's core commitment to market leadership in technology and service. We believe Don's contributions will strengthen QIAGEN's competitive advantage and benefit our customers."

QIAGEN N.V., a Netherlands holding company with subsidiaries in Germany, the United States, Japan, the United Kingdom, Switzerland, France, Australia and Canada, believes it is the world's leading provider of innovative enabling technologies and products for the separation, purification and handling of nucleic acids. The Company has developed a comprehensive portfolio of more than 260 proprietary, consumable products for nucleic acid separation, purification and handling, nucleic acid amplification, as well as automated instrumentation and related services. QIAGEN's products are sold in more than 35 countries throughout the world to academic research markets and also to leading pharmaceutical and biotechnology companies. In addition, the Company is positioning its products for sale into developing commercial markets, including DNA sequencing and genomics, nucleic acid-based molecular diagnostics, and genetic vaccination and gene therapy. QIAGEN employs approximately 750 people worldwide.

*Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products and markets and operating results are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations), variability of operating results, the commercial development of the DNA sequencing and genomics market, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN's products (including seasonal fluctuations), difficulties in successfully adapting the Company's products to integrated solutions and producing such products, and the Company's ability to identify and develop new products and to differentiate its products from competitors. For further information, refer to the discussion in reports that the Company has filed with the U.S. Securities and Exchange Commission (SEC).*

###